Patents by Inventor Simon Peter Tickle

Simon Peter Tickle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOLOGICAL PRODUCTS
    Publication number: 20210371547
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: January 19, 2021
    Publication date: December 2, 2021
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Simon Peter TICKLE, Heather Margaret LADYMAN
  • NEUTRALISING ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-17
    Publication number: 20170275355
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: March 31, 2017
    Publication date: September 28, 2017
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • BIOLOGICAL PRODUCTS
    Publication number: 20170145114
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 25, 2017
    Applicant: UCB BIOPHARMA SPRL
    Inventors: Andrew George POPPLEWELL, Simon Peter TICKLE, Heather Margaret LADYMAN
  • BIOLOGICAL PRODUCTS
    Publication number: 20160326247
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: March 14, 2016
    Publication date: November 10, 2016
    Inventors: Andrew George POPPLEWELL, Simon Peter TICKLE, Heather Margaret LADYMAN
  • NEUTRALISING ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-17
    Publication number: 20160251429
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: February 29, 2016
    Publication date: September 1, 2016
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Neutralising Antibody Molecules having Specificity for Human IL-17
    Publication number: 20150147331
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: September 18, 2014
    Publication date: May 28, 2015
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Biological products
    Patent number: 8895714
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: March 16, 2011
    Date of Patent: November 25, 2014
    Assignee: UCB Pharma S.A.
    Inventors: Simon Peter Tickle, Heather Margaret Ladyman
  • Neutralising antibody molecules having specificity for human IL-17
    Patent number: 8865167
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: December 9, 2012
    Date of Patent: October 21, 2014
    Assignee: UCB Pharma, S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Neutralising Antibody Molecules Having Specificity for Human IL-17
    Publication number: 20130245229
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: December 9, 2012
    Publication date: September 19, 2013
    Applicant: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Nucleic acid molecules encoding neutralising antibodies having specificity for human IL-17
    Patent number: 8329431
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: December 11, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • BIOLOGICAL PRODUCTS
    Publication number: 20120302739
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the clains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: July 13, 2012
    Publication date: November 29, 2012
    Inventors: ANDREW GEORGE POPPLEWELL, SIMON PETER TICKLE, HEATHER MARGARET LADYMAN
  • Neutralising antibody molecules having specificity for human IL-17
    Patent number: 8231875
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: July 31, 2012
    Assignee: UCB Pharma S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Neutralising Antibody Molecules Having Specificity for Human IL-17
    Publication number: 20120034656
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: August 26, 2011
    Publication date: February 9, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • BIOLOGICAL PRODUCTS
    Publication number: 20110165659
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the claims of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: March 16, 2011
    Publication date: July 7, 2011
    Inventors: ANDREW GEORGE POPPLEWELL, SIMON PETER TICKLE, HEATHER MARGARET LADYMAN
  • Biological products
    Patent number: 7919606
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: April 5, 2011
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Biological products
    Patent number: 7842787
    Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: November 30, 2010
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
  • BIOLOGICAL PRODUCTS
    Publication number: 20100021995
    Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
    Type: Application
    Filed: September 23, 2008
    Publication date: January 28, 2010
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Heather Margaret Ladyman
  • Biological Products
    Publication number: 20090269840
    Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Application
    Filed: October 30, 2007
    Publication date: October 29, 2009
    Applicant: CELLTECH R&D LIMITED
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison
  • Neutralising Antibody Molecules Having Specificity for Human IL-17
    Publication number: 20090117126
    Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
    Type: Application
    Filed: November 16, 2005
    Publication date: May 7, 2009
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
  • Biological products
    Patent number: 7452976
    Abstract: There are disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
    Type: Grant
    Filed: October 10, 2002
    Date of Patent: November 18, 2008
    Assignee: UCB Pharma S.A.
    Inventors: Andrew George Popplewell, Simon Peter Tickle, Karen Zinkewich-Peotti, Robert Kendall Morrison